Zydus Lifesciences has informed that it enclosed a disclosure in prescribed Form ‘C’ under regulation 7(2) of Insider Trading Regulations, received from Zydus Family Trust, Promoter of the Company with respect to sale of 5,83,000 Equity Shares of Re 1 each in the open market. The said sale is to enable the Company to comply with the requirements of minimum public shareholding as mandated under rule 19(2)(b) and 19(A) of Securities Contracts (Regulation) Rules, 1957 and regulation 38 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The above information is a part of company’s filings submitted to BSE.